Cancer Cell
Volume 33, Issue 5, 14 May 2018, Pages 829-842.e5
Journal home page for Cancer Cell

Article
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial

https://doi.org/10.1016/j.ccell.2018.04.004Get rights and content
Under a Creative Commons license
open access

Highlights

  • The HERBY trial tested the use of bevacizumab in pediatric non-brainstem HGG

  • Parallel translational biology studies highlighted the diversity of the trial cohort

  • Elevated levels of CD8+ T cells were seen in PXA-like and hypermutant tumors

  • MAPK-associated immune signatures predicted response to bevacizumab

Summary

The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term “HGG” in the pediatric population.

Keywords

immune
CD8
MAPK
hypermutator
H3F3A
pediatric high-grade glioma

Cited by (0)

29

Lead contact